Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

The employee option carries a $5.27 exercise price and four-year vesting tied to continued employment.

Rhea-AI Summary

Aardvark Therapeutics (AARD) granted one new employee an inducement stock option to purchase 60,000 common shares on October 1, 2026.

The exercise price is $5.27, equal to the stock’s closing price on the grant date. The award was granted under the 2025 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). It vests over four years: 25% on the first anniversary of the employee’s employment start date, then 1/48th of the total shares monthly thereafter, subject to continued employment.

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.60,000-share employee option at a $5.27 exercise price creates potential dilution if exercised.

Key Figures

Stock options granted: 60,000 shares Exercise price: $5.27 per share Vesting period: 4 years +2 more

Stock options granted

60,000 shares

Inducement award to one new employee

Exercise price

$5.27 per share

Equal to the closing price on the grant date

Vesting period

4 years

Option vesting schedule

Initial vesting

25%

Vests on the one-year employment anniversary

Subsequent vesting

1/48th monthly

Subject to continued employment

Key Terms

inducement award, nasdaq listing rule 5635(c)(4), small-molecule therapeutics

3 terms

inducement award financial

"one new employee was granted an inducement award"

An inducement award is a special cash or equity payment given to a new hire—often an executive or key employee—outside the company’s regular pay plans to persuade them to join. Think of it like a signing bonus that can align the new person’s goals with shareholders but also represents a cost and can reduce existing owners’ percentage of the company, so investors watch these awards for their impact on ownership and future performance.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

small-molecule therapeutics technical

"developing novel, small-molecule therapeutics to activate innate"

Small-molecule therapeutics are low-weight chemical drugs designed to enter cells and directly interact with specific proteins or pathways, like tiny keys that fit into biological locks to change how a cell works. They matter to investors because they often can be taken orally, manufactured at scale more cheaply than larger biologic drugs, and follow well-established regulatory paths, which influences development risk, time to market and production costs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that on October 1, 2026, one new employee was granted an inducement award consisting of a stock option to purchase 60,000 shares of common stock.  

The option was granted pursuant to the Aardvark Therapeutics, Inc. 2025 Inducement Equity Incentive Plan and was granted as an inducement material to the employee’s employment with Aardvark in accordance with Nasdaq Listing Rule 5635(c)(4). 

The exercise price of the option is equal to the closing price of Aardvark’s common stock on the date of grant, or $5.27. The option will vest over four years, with 25% of the total number of shares vesting on the one-year anniversary of the date of commencement of such employee’s employment with Aardvark and 1/48^th of the total number of shares subject to the option vesting monthly thereafter, subject to continued employment. 

About Aardvark Therapeutics, Inc.
Aardvark is a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi Syndrome (PWS) and metabolic diseases. Hunger, which is the discomfort from not having eaten recently, is a distinct neural signaling pathway separate from appetite, the reward-seeking desire for food. Our programs explore therapeutic applications in hunger-associated indications and potential complementary uses with anti-appetite therapies. For more information, visit www.aardvarktherapeutics.com. 

Investor and Media Contact:
Courtney Mogerley
Argot Partners
(212) 600-1902
Aardvark@Argotpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What are the terms of Aardvark Therapeutics’ October 1, 2026 inducement grant?

The grant gives one new employee an option to purchase 60,000 common shares at $5.27 per share. The exercise price equals Aardvark’s closing stock price on the grant date.

How does Aardvark Therapeutics’ employee inducement option vest?

The option vests over four years, subject to continued employment. The first 25% vests on the first anniversary of the employee’s employment start date; 1/48th of the total shares subject to the option vests monthly thereafter.